Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $40.75

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $40.75.

COLL has been the subject of a number of research reports. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research report on Friday, May 10th. Finally, Needham & Company LLC downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 19,710 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the transaction, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares in the company, valued at $3,598,549.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the transaction, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. In the last three months, insiders sold 105,502 shares of company stock valued at $3,540,796. 3.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the period. Penn Capital Management Company LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at about $9,755,000. LSV Asset Management increased its stake in shares of Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the period. New York State Common Retirement Fund boosted its position in shares of Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after purchasing an additional 188,347 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its position in Collegium Pharmaceutical by 713.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after buying an additional 111,394 shares during the last quarter.

Collegium Pharmaceutical Stock Down 0.7 %

Shares of NASDAQ COLL opened at $32.20 on Thursday. The company’s 50-day simple moving average is $33.82 and its 200-day simple moving average is $34.33. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 13.42 and a beta of 0.96. Collegium Pharmaceutical has a 52-week low of $20.83 and a 52-week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The business had revenue of $144.92 million during the quarter, compared to analysts’ expectations of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. Equities analysts predict that Collegium Pharmaceutical will post 5.57 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.